by According to Precedence Research, during the forecast period of 2022 to 2030, the global artificial intelligence (AI) in drug discovery market is estimated to develop at a compound annual growth rate (CAGR) of 29.62%. The global artificial intelligence (AI) in drug discovery market was valued at USD 1153.6 million in 2021, and it is predicted to exceed USD 11,914 million by 2030. The study investigates several elements and their consequences on the growth of the artificial intelligence (AI) in drug discovery market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1875
This report focuses on artificial intelligence (AI) in drug discovery market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall artificial intelligence (AI) in drug discovery market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
Report Scope of the Artificial Intelligence (AI) In Drug Discovery Market
| Report Coverage | Details |
| Market Size by 2030 | USD 11,914 Million |
| Growth Rate from 2022 to 2030 | CAGR of 29.62% |
| North America Market Share in 2021 | 56% |
| Drug Optimization and Repurposing Segment Market Share in 2021 | 51% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type, Application, Drug Type, Offering, Technology, End User, Geography |
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of artificial intelligence (AI) in drug discovery, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of artificial intelligence (AI) in drug discovery has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the artificial intelligence (AI) in drug discovery market.
Some of the prominent players in the artificial intelligence (AI) in drug discovery market include:
- NVIDIA CORPORATION
- Microsoft Corporation
- INSILICO MEDICINE INC.
- Schrödinger
- EXSCIENTIA
- Cloud Pharmaceuticals
- CLOUD PHARMACEUTICAL
- TOMWISE, INC
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1875
Segments Covered in the Report
By Type
- Preclinical and Clinical Testing
- Molecule Screening
- Target Identification
- De Novo Drug Design and Drug Optimization
By Application
- Neurology
- Infectious Disease
- Oncology
- Others
By Drug Type
- Small Molecules
- Large Molecules
By Offering
- Software
- Services
By Technology
- Machine Learning
- Deep Learning
- Supervised Learning
- Reinforcement Learning
- Unsupervised Learning
- Other Machine Learning Technologies
- Other Technologies
By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academics & Research
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. End User Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Artificial Intelligence (AI) In Drug Discovery Market
5.1. COVID-19 Landscape: Artificial Intelligence (AI) In Drug Discovery Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Artificial Intelligence (AI) In Drug Discovery Market, By Type
8.1. Artificial Intelligence (AI) In Drug Discovery Market, by Type, 2022-2030
8.1.1. Preclinical and Clinical Testing
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Molecule Screening
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Target Identification
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. De Novo Drug Design and Drug Optimization
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Artificial Intelligence (AI) In Drug Discovery Market, By Application
9.1. Artificial Intelligence (AI) In Drug Discovery Market, by Application, 2022-2030
9.1.1. Neurology
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Infectious Disease
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Oncology
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Artificial Intelligence (AI) In Drug Discovery Market, By Drug Type
10.1. Artificial Intelligence (AI) In Drug Discovery Market, by Drug Type, 2022-2030
10.1.1. Small Molecules
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Large Molecules
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Artificial Intelligence (AI) In Drug Discovery Market, By Offering
11.1. Artificial Intelligence (AI) In Drug Discovery Market, by Offering, 2022-2030
11.1.1. Software
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Services
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Artificial Intelligence (AI) In Drug Discovery Market, By Technology
12.1. Artificial Intelligence (AI) In Drug Discovery Market, by Technology, 2022-2030
12.1.1. Machine Learning
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Other Technologies
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Artificial Intelligence (AI) In Drug Discovery Market, By End User
13.1. Artificial Intelligence (AI) In Drug Discovery Market, by End User, 2022-2030
13.1.1. Pharmaceutical & Biotechnology Companies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Contract Research Organizations
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Academics & Research
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Others
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Artificial Intelligence (AI) In Drug Discovery Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Application (2017-2030)
14.1.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.4. Market Revenue and Forecast, by Offering (2017-2030)
14.1.5. Market Revenue and Forecast, by Technology (2017-2030)
14.1.6. Market Revenue and Forecast, by End User (2017-2030)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.7.2. Market Revenue and Forecast, by Application (2017-2030)
14.1.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.7.4. Market Revenue and Forecast, by Offering (2017-2030)
14.1.8. Market Revenue and Forecast, by Technology (2017-2030)
14.1.8.1. Market Revenue and Forecast, by End User (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Application (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Offering (2017-2030)
14.1.10. Market Revenue and Forecast, by Technology (2017-2030)
14.1.11. Market Revenue and Forecast, by End User (2017-2030)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.4. Market Revenue and Forecast, by Offering (2017-2030)
14.2.5. Market Revenue and Forecast, by Technology (2017-2030)
14.2.6. Market Revenue and Forecast, by End User (2017-2030)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.9. Market Revenue and Forecast, by Offering (2017-2030)
14.2.10. Market Revenue and Forecast, by Technology (2017-2030)
14.2.10.1. Market Revenue and Forecast, by End User (2017-2030)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.12. Market Revenue and Forecast, by Offering (2017-2030)
14.2.13. Market Revenue and Forecast, by Technology (2017-2030)
14.2.14. Market Revenue and Forecast, by End User (2017-2030)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.15.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.15.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.15.4. Market Revenue and Forecast, by Offering (2017-2030)
14.2.16. Market Revenue and Forecast, by Technology (2017-2030)
14.2.16.1. Market Revenue and Forecast, by End User (2017-2030)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.17.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.17.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.17.4. Market Revenue and Forecast, by Offering (2017-2030)
14.2.18. Market Revenue and Forecast, by Technology (2017-2030)
14.2.18.1. Market Revenue and Forecast, by End User (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.4. Market Revenue and Forecast, by Offering (2017-2030)
14.3.5. Market Revenue and Forecast, by Technology (2017-2030)
14.3.6. Market Revenue and Forecast, by End User (2017-2030)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.7.4. Market Revenue and Forecast, by Offering (2017-2030)
14.3.8. Market Revenue and Forecast, by Technology (2017-2030)
14.3.9. Market Revenue and Forecast, by End User (2017-2030)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Offering (2017-2030)
14.3.11. Market Revenue and Forecast, by Technology (2017-2030)
14.3.11.1. Market Revenue and Forecast, by End User (2017-2030)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.12.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.12.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.12.4. Market Revenue and Forecast, by Offering (2017-2030)
14.3.12.5. Market Revenue and Forecast, by Technology (2017-2030)
14.3.12.6. Market Revenue and Forecast, by End User (2017-2030)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.13.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.13.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.13.4. Market Revenue and Forecast, by Offering (2017-2030)
14.3.13.5. Market Revenue and Forecast, by Technology (2017-2030)
14.3.13.6. Market Revenue and Forecast, by End User (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.4. Market Revenue and Forecast, by Offering (2017-2030)
14.4.5. Market Revenue and Forecast, by Technology (2017-2030)
14.4.6. Market Revenue and Forecast, by End User (2017-2030)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.7.4. Market Revenue and Forecast, by Offering (2017-2030)
14.4.8. Market Revenue and Forecast, by Technology (2017-2030)
14.4.9. Market Revenue and Forecast, by End User (2017-2030)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Offering (2017-2030)
14.4.11. Market Revenue and Forecast, by Technology (2017-2030)
14.4.12. Market Revenue and Forecast, by End User (2017-2030)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.13.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.13.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.13.4. Market Revenue and Forecast, by Offering (2017-2030)
14.4.13.5. Market Revenue and Forecast, by Technology (2017-2030)
14.4.13.6. Market Revenue and Forecast, by End User (2017-2030)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.14.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.14.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.14.4. Market Revenue and Forecast, by Offering (2017-2030)
14.4.14.5. Market Revenue and Forecast, by Technology (2017-2030)
14.4.14.6. Market Revenue and Forecast, by End User (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Application (2017-2030)
14.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.4. Market Revenue and Forecast, by Offering (2017-2030)
14.5.5. Market Revenue and Forecast, by Technology (2017-2030)
14.5.6. Market Revenue and Forecast, by End User (2017-2030)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.7.2. Market Revenue and Forecast, by Application (2017-2030)
14.5.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.7.4. Market Revenue and Forecast, by Offering (2017-2030)
14.5.8. Market Revenue and Forecast, by Technology (2017-2030)
14.5.8.1. Market Revenue and Forecast, by End User (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Application (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Offering (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Technology (2017-2030)
14.5.9.6. Market Revenue and Forecast, by End User (2017-2030)
Chapter 15. Company Profiles
15.1. NVIDIA CORPORATION
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Microsoft Corporation
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. INSILICO MEDICINE INC.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Schrödinger
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. EXSCIENTIA
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Cloud Pharmaceuticals
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. TOMWISE, INC
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1875
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
